Author: Stephania Klemp

The European Commission (EC) has fined pharmaceutical company Teva €462.6 million for “systematically spread[ing] misleading information” and abusing its dominant position to delay competition to its proprietary multiple sclerosis drug Copaxone (glatiramer acetate). The delay may have prevented “significant savings” for public health budgets, according to a statement by EC executive vice president Margrethe Vestager…